NMN/NR Dosing in Renal Impairment: Evidence-Based Adjustments for Kidney Disease

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are NAD+ precursor supplements, not FDA-approved drugs. Neither has been studied in a controlled trial that enrolled participants with reduced kidney function, so there is no regulatory or trial-based renal dosing schedule for either compound. That gap matters because the metabolites both compounds generate downstream, nicotinamide and its methylated and pyridone breakdown products, are cleared primarily by the kidney, using pathways that are well established for the related vitamin niacin but have not been directly measured for NMN or NR in people with chronic kidney disease (CKD).

The practical position this page takes: in the absence of direct evidence, the safest approach for anyone with an eGFR below 60 mL/min/1.73 m² who chooses to use NMN or NR is to start at the lowest dose used in published healthy-population trials, avoid escalation, and monitor standard renal and metabolic labs more frequently than a healthy user would, not because harm has been demonstrated, but because the mechanism for slower metabolite clearance is plausible and unstudied. This is an extrapolation from related pharmacology, not a validated clinical protocol, and readers should not treat it as one.

What is established, what is plausible, and what is not known

Established: NMN and NR are converted to NAD+ through distinct entry points into the NAD+ salvage pathway (NMN via NMNAT enzymes; NR via nicotinamide riboside kinases), and both ultimately generate nicotinamide and its downstream methylated metabolite, which the kidney excretes. This basic biochemistry is well characterized in the general NAD+ metabolism literature. Niacin (a related B3-vitamin form with a shared clearance pathway) carries prescribing caution for renal impairment, which is the closest analogous precedent available.

Plausible but unproven: that reduced glomerular filtration slows clearance of NAD+ precursor metabolites in a way that raises plasma concentrations at standard doses; that this accumulation could theoretically add methylation burden or elevate homocysteine; that competition between nicotinamide and uric acid for renal tubular secretion could matter more in patients who already have impaired urate clearance. These are reasonable inferences from adjacent pharmacology, not findings from a trial in CKD patients.

Not established: any human safety or efficacy data for NMN or NR at any dose in patients with eGFR below 60 mL/min/1.73 m². No published randomized trial of either compound has enrolled participants with kidney disease. Animal studies showing NAD+ repletion protects kidney tissue in acute injury models used doses far above what is used in human supplementation and cannot be assumed to apply at human-tolerable doses. Whether hemodialysis or peritoneal dialysis clears these metabolites has not been measured.

This is the single fact-dense summary worth repeating: no regulatory body or controlled human trial has established a safe or effective renal dose for NMN or NR, the compounds' downstream metabolites depend on renal excretion by analogy with niacin pharmacology, and every dosing recommendation below is a cautious extrapolation pending direct study, not a validated clinical guideline.

Why the kidney matters for these specific compounds

NAD+ generated from NMN or NR is broken down into nicotinamide and then into methylated and pyridone byproducts. In people with normal kidney function these are cleared efficiently. As filtration declines, clearance of small, water-soluble metabolites like these would be expected to slow, this is a general principle of renal pharmacology that applies to many small-molecule metabolites, not a finding specific to NMN or NR trials. Because no pharmacokinetic study of NMN or NR has been conducted in CKD, the magnitude of any slowdown, and whether it produces a clinically meaningful accumulation, is unknown.

Separately, CKD is associated with reduced NAD+ availability in kidney tissue in animal models, which is the biological rationale researchers cite for testing NAD+ precursors as a potential kidney-protective therapy. That rationale is a hypothesis under active investigation, not a demonstrated human benefit. The two facts sit in tension: the population that might theoretically benefit most from NAD+ repletion is also the population where metabolite clearance is most likely to be impaired, and neither side of that tension has direct human data.

Should dosing change based on kidney function?

There is no trial evidence to answer this directly. What follows is a cautious, mechanism-based framework, not a guideline, and it should be applied only with clinician involvement, especially for anyone with eGFR below 60.

A decision framework for NMN/NR use across CKD stages

The table is a synthesis of general renal pharmacology principles and the acknowledged absence of direct trial data. It is meant to organize a conversation with a treating clinician, not to substitute for one, and it will need revision if and when controlled trials in CKD populations report results.

What labs make sense to track, and why

Because no NMN- or NR-specific renal monitoring protocol has been validated, the most defensible approach borrows from how clinicians already monitor niacin and general metabolic supplementation in kidney disease:

• Renal function (creatinine, eGFR): the primary safety signal. A meaningful rise from baseline after starting or increasing a dose is a reason to hold the supplement and reassess, recognizing that CKD progresses for many reasons unrelated to any supplement.
• Uric acid: nicotinamide and uric acid share a renal tubular secretion pathway in principle; patients with CKD often already have impaired urate excretion, so this is a reasonable value to track even though no NMN/NR-specific trial has quantified the effect.
• Homocysteine: converting nicotinamide to its methylated metabolite consumes methyl donors; CKD patients often have elevated homocysteine at baseline. Whether NAD+ precursor supplementation raises it meaningfully in this population is untested.
• Liver enzymes: relevant because hepatic conversion of NMN/NR to NAD+ is the rate-limiting step upstream of renal clearance, and liver function is generally preserved separately from kidney function.

Specialty labs can measure plasma methylated nicotinamide and pyridone metabolites directly, but these are not standard clinical tests, have no established reference range in CKD, and should be treated as exploratory if ordered.

Medication interactions worth raising with a prescriber

Patients with CKD stage 3 or beyond are frequently on multiple medications, and a few classes deserve a specific conversation before adding NMN or NR:

• Allopurinol or febuxostat: both affect purine metabolism; there is no interaction study with NMN/NR, but more frequent uric acid checks are reasonable if combined.
• Metformin: requires its own dose adjustment or discontinuation at low eGFR under FDA labeling, independent of any NAD+ precursor use. Adding NMN or NR does not change metformin's renal dosing rules.
• ACE inhibitors or ARBs: no known interaction; some animal research has explored whether NAD+ repletion offers additional kidney protection alongside these drugs, but this has not been tested in humans and should not change how these medications are dosed.
• Phosphate binders (e.g., sevelamer, lanthanum): as a general precaution, separating any oral supplement from phosphate binders by a couple of hours avoids potential binding interference in the gut, though this has not been specifically studied for NMN or NR.

The regulatory picture, as of this writing

NMN's regulatory status in the United States has been unsettled: the FDA took the position that NMN could not be marketed as a dietary supplement because it was under investigation as a new drug, a determination that has been contested and remains subject to ongoing developments. Readers should check the FDA's dietary supplement pages for the current status rather than relying on a fixed date, since this is a volatile regulatory question (FDA Dietary Supplement Products & Ingredients). NR has generally been marketed under New Dietary Ingredient and GRAS pathways, which do not require special-population safety testing in kidney or liver impairment. Neither pathway constitutes FDA drug approval, and neither has produced renal dosing guidance.

This regulatory gap is the reason no official renal dosing chart exists for either compound. It should not be read as reassurance that the compounds are safe in kidney disease, it reflects the lower evidentiary bar dietary supplements face compared with prescription drugs, not an absence of concern.

Research that may eventually close this gap

Interest in NAD+ precursors as a kidney-protective therapy has generated animal studies and some early clinical investigation, including trials specifically enrolling patients with reduced kidney function. Readers interested in whether a relevant trial is currently recruiting can check a registry search directly rather than relying on any specific identifier repeated secondhand, since trial status changes over time (search "nicotinamide riboside kidney" or "NMN chronic kidney disease" at clinicaltrials.gov). Until results from trials that specifically enroll CKD patients are published and independently reviewed, any claim about renal benefit or renal safety at a specific dose should be treated as unverified.

When to involve a nephrologist or seek urgent care

Anyone with CKD stage 3 or worse who is considering NMN or NR should discuss it with their nephrologist or primary treating clinician before starting, given the complete absence of safety data at reduced filtration rates. Seek prompt medical attention rather than adjusting a supplement independently if a person on NMN or NR develops new swelling, a significant drop in urine output, unexplained muscle pain, or lab results showing a substantial rise in creatinine, these warrant evaluation regardless of whether the supplement is the cause.